Site Search
Displaying results 1 - 10 of 13
Resource | Reviews and Snapshots,
Marked inequalities and diverse epidemic trends affect progress in the HIV response in Asia and the Pacific. The HIV epidemic in the region disproportionately affects people from key populations, especially young people (aged 15–24 years), and their sexual partners. Download the regional factsheet to find out the most up-to-date HIV info, data and analysis.
Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy: Annexes
Resource | Reviews and Snapshots,
The aim of this review was to determine if packaged interventions, which include enhanced infection prophylaxis, screening, and other elements of care delivered together, can improve outcomes in HIV-positive patients presenting with advanced disease.
Resource | Reviews and Snapshots,
The world has embraced the UNAIDS 90–90–90 treatment target, whereby 90% of people living with HIV know their HIV status, 90% of people who know their HIV-positive status are accessing antiretroviral treatment, and 90% of people on treatment have suppressed viral loads. By reaching the 90–90–90 treatment target by 2020, the world will be firmly on track towards ending the AIDS epidemic by 2030.
Resource | Reviews and Snapshots,
More than 2 million new HIV infections occurred in 2014—two thirds occurred in sub-Saharan Africa. The speed at which new HIV infections are declining needs to accelerate in order to meet the UNAIDS Fast-Track Targets by 2020.
The UNAIDS Fast-Track prevention target is to reduce the number of new HIV infections to fewer than 500 000 annually by 2020, a reduction of 75% over the next few years.
By scaling up both treatment and HIV prevention, and front-loading investments, around 17.6 million new HIV infections can be averted between 2015 and 2030.
By investing in averting new HIV infections, the future costs of treatment will be reduced and HIV prevention and treatment programmes can be sustained.
Resource | Reviews and Snapshots,
This paper reviews the latest global and local situation of hepatitis A and examines the prevention and control measures of hepatitis A in Hong Kong.
Hepatitis A is inflammation of the liver caused by the hepatitis A virus (HAV). It is one of the most frequent causes of foodborne infection. It occurs sporadically and in epidemics worldwide. Every year there are an estimated 1.4 million cases of hepatitis A worldwide. Regions with high HAV endemicity include parts of Africa and Asia. The disease is closely associated with unsafe water, inadequate sanitation and poor personal hygiene.
Resource | Reviews and Snapshots,
In the past 15 years, global progress against AIDS has been significant. Yet achievements have been unequal. Throughout the world, stigma, discrimination and exclusion, as well as imbalanced power and gender relations, continue to make women and girls, young people and key populations vulnerable to HIV and hinder access to HIV prevention, treatment and care services.
The AIDS response has demonstrated the importance and feasibility of overcoming human rights, gender-related and legal barriers to HIV services. The vision of zero discrimination put forward in the UNAIDS 2009–2015 Strategy and endorsed by the 2011 Political Declaration on HIV and AIDS has inspired action in advocacy, litigation and law reform for the right to health, including access to essential medicines.
Resource | Reviews and Snapshots,
By 2020, 90% of all people living with HIV will know their HIV status. By 2020, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy. By 2020, 90% of all people receiving antiretroviral therapy will have durable viral suppression. When these targets are achieved, at least 73% of all people living with HIV worldwide will be virally suppressed—a three-fold increase over current estimates of viral suppression. Modelling demonstrates that achieving these targets by 2020 will enable us to end the AIDS epidemic by 2030.
Resource | Reviews and Snapshots,
The report provides an overview of the patent landscape with respect to a select number of antiretroviral (ARV) medicines in developing countries as of April 2014. The focus is primarily on those ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.
Part 1 provides a brief introduction to patents and licences and their effect on the market for ARVs. It introduces key concepts that will facilitate an understanding of the report. It also explains which data sources were used for the report and notes a number of disclaimers with regard to the information contained in the report.
Part 2 is the core of the report. It outlines the patent status and licensing status of each ARV in the 81 developing countries for which data are available. For each ARV the report indicates whether that ARV is included in fixed-dose combinations for which there may be patents. General conclusions are drawn in light of the data. The key purpose is to provide an overview of the patent landscape for each ARV and, in particular, to show in which countries market competition for a given ARV is possible in view of existing patents and licences.
Resource | Reviews and Snapshots,
Bhutan is considered a low HIV prevalence country, with an estimated prevalence of 0.2% among adults aged 15-49 as of 2009; there are an estimated fewer than 1,000 [<1,000-1,500] adults and children currently living with HIV in the country.